kynurenic acid

(redirected from Kynurenic)
Also found in: Dictionary, Encyclopedia, Wikipedia.

kyn·u·ren·ic ac·id

(kin'yū-rē'nik as'id, -ren'ik),
A product of the metabolism of l-tryptophan; appears in human urine in states of marked pyridoxine deficiency.
Farlex Partner Medical Dictionary © Farlex 2012

ky·nu·ren·ic ac·id

(kin-yūr-ē'nik as'id)
A product of the metabolism of l-tryptophan; appears in urine in pyridoxine deficiency.
Medical Dictionary for the Health Professions and Nursing © Farlex 2012
References in periodicals archive ?
Xanthurenic Acid, Kynurenic Acid, and Blood Sugar Regulation
To achieve more discriminative power, a biomarker group was generated including 6 upregulated (creatine, tryptophan, N-acetylhistidine, L-carnitine, pyroglutamic acid, and indoleacrylic acid) and 10 downregulated (prolinebetaine, L-acetylcarnitine, pipecolic acid, xanthurenic acid, trigonelline, kynurenic acid, indole-3-carboxylic acid, phosphorylcholine, 4-pyridoxic acid, and thymine) metabolites with AUC > 0.85.
Liu et al., "Kynurenic acid, an IDO metabolite, controls TSG-6-mediated immunosuppression of human mesenchymal stem cells," Cell Death & Differentiation, vol.
Quinaldic acid (0.103 mmol; 17.8 mg) or kynurenic acid (0.103 mmol; 19.5 mg), respectively, for synthesis of complexes 1 and 2, was solubilized in 10 mL of methanol and deprotonated with triethylamine (0.132 mmol; 0.014 ml) and this solution was added dropwise on the precursor solution.
It was shown that proinflammatory cytokines, such as IL-1[beta], and reactive oxygen species can enhance the activity of IDO, which catabolizes tryptophan into kynurenine, which is further catabolized into kynurenic acid and quinolinic acid [46].
The induction of IDO and TDO leads to increased concentration of kynurenine pathway metabolites, mostly kynurenic acid and quinolinic acid.
To assess the herbs' effect on mitochondria membrane potential upon [MPP.sup.+] treatment, SH-SY5Y cells were pre-treated with NTNU-319, 379, 395 or 439 (10 [micro]g/ml) for 8 h followed by [MPP.sup.+] treatment (3.0 mM) for 24 h Kynurenic acid (KYNA), a tryptophan metabolite known to own mitochondrial protection effect and attenuate [MPP.sup.+]-induced neuronal cell death in SH-SY5Y cells (Lee et al., 2008) was included as a positive compound for comparison.
One of the most studied metabolites of the kynurenine pathway is kynurenic acid (KYNA), which is so far the only known endogenous NMDA receptor antagonist.
However, we showed previously that, in Goldblatt 2-kidneys, one-clip (2K1C) model, microinjection of kynurenic acid, a broad spectrum EAA receptor antagonist, into the RVLM, reduced BP to the same extent as autonomic blockade [5].
A synthetic analogue of kynurenic acid, a naturally occurring neural regulatory compound, 7-C1KYNA is one of the most potent and selective blockers of the regulatory GlyB-site of the NMDA receptor.
Schroeder et al., "Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling," Toxicological Sciences, vol.